Nasal, decongestant, and anaphylaxis agents
| Drug monograph · NCLEX study reference | |
| Trade names | Afrin, EpiPen |
|---|---|
| Therapeutic class | Allergy and ENT agents |
| Pharmacologic class | Intranasal corticosteroids, intranasal antihistamine, oral and topical decongestants, adrenergic agonist (epinephrine), mast cell stabilizer (cromolyn) |
| Onset / peak / duration | Intranasal steroids build over days; decongestants and epinephrine act quickly. |
| Half-life / level | Varies; no routine level. |
| Routes | PO (oral), IM, Intranasal |
| High-alert (ISMP) | No |
| Black box warning | None |
| Antidote / reversal | Supportive care. |
| Pregnancy / lactation | Use intranasal steroids and epinephrine when needed. |
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Nasal, decongestant, and anaphylaxis agents (brand names Afrin, EpiPen) — Allergy and ENT agents; Intranasal corticosteroids, intranasal antihistamine, oral and topical decongestants, adrenergic agonist (epinephrine), mast cell stabilizer (cromolyn).
Identification
- Therapeutic class: Allergy and ENT agents.
- Pharmacologic class: Intranasal corticosteroids, intranasal antihistamine, oral and topical decongestants, adrenergic agonist (epinephrine), mast cell stabilizer (cromolyn).
Pharmacology
- Mechanism of action: Reduce nasal inflammation (steroids), block histamine (azelastine), constrict nasal vessels (decongestants), reverse anaphylaxis (epinephrine), or stabilize mast cells (cromolyn).
- Onset / peak / duration: Intranasal steroids build over days; decongestants and epinephrine act quickly.
- Half-life / therapeutic level: Varies; no routine level.
Clinical use
- Indications: Allergic rhinitis (steroids, azelastine, cromolyn), nasal congestion (decongestants), anaphylaxis (epinephrine).
- Usual dose, route, frequency: Intranasal sprays daily; pseudoephedrine PO; oxymetazoline nasal short term; epinephrine IM for anaphylaxis.
- Maximum dose / adjustments: Oxymetazoline limited to 3 days (rebound congestion); pseudoephedrine caution with hypertension.
Safety
- Contraindications: Decongestants in uncontrolled hypertension, severe coronary disease; with MAO inhibitors.
- Black box warning: None for these.
- Interactions: Decongestants with MAO inhibitors (hypertensive crisis) and other stimulants; epinephrine with beta blockers (blunted response).
- Pregnancy / lactation: Use intranasal steroids and epinephrine when needed.
- High-alert: No.
Adverse effects
- Common side effects: Nasal irritation and epistaxis (steroids), bitter taste (azelastine), insomnia and elevated blood pressure (decongestants).
- Serious effects to report: Rebound congestion (oxymetazoline overuse), severe hypertension (decongestants), epinephrine cardiac effects.
- Antidote / reversal: Supportive care.
Nursing process
- Assessment before administration: Allergy symptoms, blood pressure (decongestants), anaphylaxis assessment (epinephrine).
- Interventions during therapy: For anaphylaxis, give epinephrine IM in the lateral thigh immediately and call emergency services; aim nasal sprays away from the septum.
- Monitor: Symptom relief, blood pressure (decongestants), response to epinephrine.
- Evaluation / expected outcome: Reduced allergy symptoms or reversed anaphylaxis.
Patient teaching
- Patient teaching: Nasal steroids take days and may cause nosebleeds (aim away from the septum); do not use Afrin more than 3 days; carry and know how to use the epinephrine autoinjector and seek emergency care after using it.
- Notify provider if: Severe nosebleeds, palpitations or high blood pressure, any anaphylaxis (after using epinephrine, still seek emergency care).
- Administration tips: Epinephrine IM lateral thigh for anaphylaxis; oxymetazoline short term only.